Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04757974 · ClinicalTrials.gov registry record · Phase 1
Low-dose Fostemsavir Extended Release Relative Bioavailability Study
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04757974 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 32 participants.
The verdict
NCT04757974, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a two-part study. Part 1 will evaluate relative bioavailability of temsavir (TMR) following single dose administration of the reference fostemsavir (FTR) compared to two low-dose ER tablet formulations of FTR. In Part 2, the effect of food on the bioavailability of TMR will be assessed on the selected low-dose ER tablet formulation from Part 1.
Interventions
- DRUG Fostemsavir 600 mg
- DRUG Fostemsavir 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04757974
The ClinicalTrials.gov registry entry for NCT04757974 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fostemsavir 600 mg is the first listed.
NCT04757974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04757974 about?
NCT04757974 is a clinical study titled "Low-dose Fostemsavir Extended Release Relative Bioavailability Study". This is a two-part study. Part 1 will evaluate relative bioavailability of temsavir (TMR) following single dose administration of the reference fostemsavir (FTR) compared to two low-dose ER tablet formulations of FTR. In Part 2, the effect of food on the bioavailability of TMR will be assessed on th...
What is the current status of trial NCT04757974?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-03-05. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT04757974?
The interventions under investigation include: Fostemsavir 600 mg (DRUG), Fostemsavir 200 mg (DRUG).
Who is sponsoring clinical trial NCT04757974?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.